



## APPENDIX

### PENDING CLAIMS

1           3. A system for averting undesirable drug interaction between a drug  
2 and concomitant drug(s), both of which are metabolized by the same molecular species of  
3 drug-metabolizing enzyme in humans, or between a drug and concomitant drug(s) that is  
4 metabolized by the molecular species of drug-metabolizing enzymes that is inhibited by  
5 the said drug, which comprises timed-release control of the said drug or control of the site  
6 of release of the said drug to the digestive tract.

1           4. A system for averting undesirable drug interaction between a drug  
2 and concomitant drug(s), both of which are metabolized by the drug metabolizing enzyme  
3 CYP3A4, or between a drug that inhibits CYP3A4 and concomitant drug(s) that is  
4 metabolized by CYP3A4, which comprises timed-release control of the said drug or  
5 controlling release specifically in the lower digestive tract of the said drug.

1           7. A drug preparation for averting undesirable drug interaction on the  
2 *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the  
3 said drug in humans, which comprises timed-release control of the concomitant drug or  
4 control of the site of release of the concomitant drug to the digestive tract.

1           8. A drug preparation for averting undesirable effects on the blood  
2 concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the  
3 said drug by CYP3A4 in humans, which comprises timed release control of the said drug  
4 or controlling release specifically in the lower digestive tract of the concomitant drug.

1           9. The drug preparation according to Claim 8, whereby the said drug  
2 and the concomitant drug are a combination selected from anfentanyl, fentanyl,  
3 sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin,  
4 clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone,  
5 midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,

6 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nldipine,  
7 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,  
8 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,  
9 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,  
10 pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,  
11 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,  
12 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,  
13 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,  
14 ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and  
15 conivaptan.

1           12. A method for averting undesirable drug-interaction on the *in vivo*  
2 kinetics of a drug by concomitant drug that inhibits the *in vivo* metabolism of the said  
3 drug by drug-metabolizing enzymes in humans, comprising administering to patients a  
4 drug preparation with which timed-release of the concomitant drug or release site of the  
5 concomitant drug to the digestive tract is controllable.

1           13. A method for averting undesirable effects on the blood  
2 concentration of a drug by concomitant drug that inhibits the *in vivo* metabolism of the  
3 said drug by CYP3A4, comprising administering to patients a drug preparation with  
4 which timed-release of the concomitant drug or release of the concomitant drug  
5 specifically to the lower digestive tract is controllable.

1           14. The method according to Claim 13, whereby the said drug and the  
2 concomitant drug are a combination selected from anfentanyl, fentanyl, sulfentanyl,  
3 cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin, clarithromycin,  
4 troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone, midazolam,  
5 triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine, nitrendipine,  
6 amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nldipine, bepridil,  
7 diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine, tacrolimus,  
8 rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine, imipramine,  
9 amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol, pimozide,

10 carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin, fluvastatin,  
11 atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine, vincristine,  
12 indinavir, ritonavir, saquinavir, testosterone, prednisolone, methylprednisolone,  
13 dexamethasone, proguanil, warfarin, finasteride, flutamide, ondansteron, zatsetrone,  
14 cisapride, cortisol, zonisamide, desmethyl diazepam, and conivaptan.

1                 16. A drug preparation for averting undesirable effects on the blood  
2 concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the  
3 said drug by CYP3A4 in humans, which comprises timed release control of the said drug  
4 or controlling release specifically in the lower digestive tract of the concomitant drug,  
5 whereby:

6                 the said drug and the concomitant drug are a combination selected from  
7 alfentanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,  
8 erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,  
9 dapson, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,  
10 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,  
11 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratadine, cyclosporine,  
12 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,  
13 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,  
14 pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,  
15 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,  
16 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,  
17 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,  
18 ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyl diazepam, and  
19 conivaptan.

1                 17. A drug preparation for averting undesirable drug interaction on the  
2 *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the  
3 said drug in humans, which comprises timed-release control of the concomitant drug or  
4 control of the site of release of the concomitant drug to the digestive tract whereby:

5                   the said drug and the concomitant drug are a combination selected from  
6       anfentanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,  
7       erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,  
8       dapsone, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,  
9       nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,  
10      bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,  
11      tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,  
12      imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,  
13      pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,  
14      fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,  
15      vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,  
16      methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,  
17      ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and  
18      conivaptan.

1                   18. (New)     The system for averting undesirable drug interaction of  
2       claim 3, wherein said drug and the concomitant drug are both metabolized by the same  
3       molecular species of drug-metabolizing enzyme in humans.

1                   19. (New)     The system for averting undesirable drug interaction of  
2       claim 3, wherein the concomitant drug is metabolized by the molecular species of the  
3       drug-metabolizing enzymes that is inhibited by the said drug.

1                   20. (New)     The system for averting undesirable drug interaction of  
2       claim 18, wherein said drug and the concomitant drug are both metabolized by CYP3A4.

1                   21. (New)     The system for averting undesirable drug interaction of  
2       claim 19, the concomitant drug is metabolized by CYP3A4 and said drug inhibits  
3       CYP3A4.